Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2021 / N 4

Лекарственно-индуцированные обострения бронхиальной астмы и бронхоспазм
В.А. Де, А.И. Кочетков, В.В. Когай, И.Ф. Кроткова, О.Д. Остроумова

Список литературы

1. Global Initiative for Asthma. 2021 GINA main report. Global strategy for asthma management and prevention. Updated 2021. Available from: https://ginasthma.org/gina-reports/ Accessed 2022 Feb 24.
2. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease study 2019. The Lancet 2020 Oct;396(10258):1204-22.
3. Chuchalin AG, Khaltaev N, Аntonov N, Galkin DV, Manakov LG, Antonini P, Murphy M, Solodovnikov AG, Bousquet J, Pereira MHS, Demko IV. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. International Journal of Chronic Obstructive Pulmonary Disease 2014 Sep;9:963-74.
4. Министерство здравоохранения Российской Федерации. Статистический сборник 2017 г. Общая заболеваемость всего населения в 2017 году. Доступно по: https://minzdrav.gov.ru/ministry/61/22/stranitsa-979/statisticheskie-i-informatsionnye-materialy/statisticheskiy-sbornik-2017-god Ссылка активна на 24.02.2022.
5. National Asthma Education and Prevention Program; Third Expert Panel on the Diagnosis and Management of Asthma. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute; 2007. Available from: https://www.ncbi.nlm.nih.gov/books/NBK7232/ Accessed 2022 Feb 2022.
6. Covar RA, Macomber BA, Szefler SJ. Medications as asthma triggers. Immunology and Allergy Clinics of North America 2005 Feb;25(1):169-90.
7. Babu KS, Marshall BG. Drug-induced airway diseases. Clinics in Chest Medicine 2004 Mar;25(1):113-22.
8. Сычев Д.А., Остроумова О.Д., Переверзев А.П., Кочетков А.И., Остроумова Т.М., Клепикова М.В., Аляутдинова И.А., Голобородова И.В. Лекарственно-индуцированные заболевания: подходы к диагностике, коррекции и профилактике. Фармаконадзор. Фарматека 2020;27(6):113-26.
9. Camus P. The drug-induced respiratory disease website. Available from: www.pneumotox.com Accessed 2022 Feb 24.
10. Kupczyk M, Kupryś I, Górski P, Kuna P. Aspirin intolerance and allergy to house dust mites: important factors associated with development of severe asthma. Annals of Allergy, Asthma & Immunology 2004 Apr;92(4):453-8.
11. Mascia K, Haselkorn T, Deniz YM, Miller DP, Bleecker ER, Borish L; TENOR Study Group. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. The Journal of Allergy and Clinical Immunology 2005 Nov;116(5):970-5.
12. Plaza V, Serrano J, Picado C, Sanchis J; High Risk Asthma Research Group. Frequency and clinical characteristics of rapid-onset fatal and near-fatal asthma. The European Respiratory Journal 2002 May;19(5):846-52.
13. Ta V, White AA. Survey-defined patient experiences with aspirin exacerbated respiratory disease. The Journal of Allergy and Clinical Immunology. In Practice 2015 Sep-Oct;3(5):711-8.
14. Bennett M, Chang CL, Tatley M, Savage R, Hancox RJ. The safety of cardioselective β1-blockers in asthma: literature review and search of global pharmacovigilance safety reports. ERJ. Open Research 2021 Mar;7(1):00801-2020.
15. Fraunfelder FT, Barker AF. Respiratory effects of timolol. The New England Journal of Medicine 1984 Nov;311(22):1441.
16. Taniguchi M, Kino H, Mori M, Nakahama M. [A case of fatal asthma induced by timolol eye-drop]. Nihon Kyobu Shikkan Gakkai Zasshi 1990 Jan;28(1):156-9.
17. Воржева И.И., Черняк Б.А. Аспирин-индуцированное респираторное заболевание: механизмы развития, диагностика и лечение. Фарматека 2018;8(361):24-33.
18. Steinke JW, Wilson JM. Aspirin-exacerbated respiratory disease: pathophysiological insights and clinical advances. Journal of Asthma and Allergy 2016 Mar;9:37-43.
19. Tuttle KL, Schneider TR, Henrickson SE, Morris D, Abonia JP, Spergel JM, Laidlaw TM. Aspirin-exacerbated respiratory disease: not always “adult-onset”. The Journal of Allergy and Clinical Immunology. In Practice 2016;4(4):756-8.
20. Guillén D, Bobolea L, Calderon O, Fiandor A, Cabañas R, Heredia R, Quirce S. Aspirin desensitization achieved after omalizumab treatment in a patient with aspirin exacerbated urticaria and respiratory disease. Journal of Investigational Allergology and Clinical Immunology 2015;25(2):133-5.
21. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clinical Pharmacology & Therapeutics 1981 Aug;30(2):239-45.
22. Министерство здравоохранения Российской Федерации; Российское респираторное общество; Российская ассоциация аллергологов и клинических иммунологов. Клинические рекомендации. Бронхиальная астма. Год утверждения (частота пересмотра): 2018 (пересмотр каждые 3 года). М., 90 с. Доступно по: https://spulmo.ru/download/asthma2018.pdf Ссылка активна на 24.02.2022.
23. Sommer DD, Rotenberg BW, Sowerby LJ, Lee JM, Janjua A, Witterick IJ, Monteiro E, Gupta MK, Au M, Nayan S. A novel treatment adjunct for aspirin exacerbated respiratory disease: the low-salicylate diet: a multicenter randomized control crossover trial. International Forum of Allergy & Rhinology 2016 Apr;6(4):385-91.

References

1. Global Initiative for Asthma. 2021 GINA main report. Global strategy for asthma management and prevention. Updated 2021. Available from: https://ginasthma.org/gina-reports/ Accessed 2022 Feb 24.
2. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease study 2019. The Lancet 2020 Oct;396(10258):1204-22.
3. Chuchalin AG, Khaltaev N, Аntonov N, Galkin DV, Manakov LG, Antonini P, Murphy M, Solodovnikov AG, Bousquet J, Pereira MHS, Demko IV. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. International Journal of Chronic Obstructive Pulmonary Disease 2014 Sep;9:963-74.
4. Ministry of Health of the Russian Federation. Statistical collection of 2017. Total morbidity of the entire population in 2017. Available from: https://minzdrav.gov.ru/ministry/61/22/stranitsa-979/statisticheskie-i-informatsionnye-materialy/statisticheskiy-sbornik-2017-god Accessed 2022 Feb 24. (In Russian).
5. National Asthma Education and Prevention Program; Third Expert Panel on the Diagnosis and Management of Asthma. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute; 2007. Available from: https://www.ncbi.nlm.nih.gov/books/NBK7232/ Accessed 2022 Feb 2022.
6. Covar RA, Macomber BA, Szefler SJ. Medications as asthma triggers. Immunology and Allergy Clinics of North America 2005 Feb;25(1):169-90.
7. Babu KS, Marshall BG. Drug-induced airway diseases. Clinics in Chest Medicine 2004 Mar;25(1):113-22.
8. Sychev DA, Ostroumova OD, Pereverzev AP, Kochetkov AI, Ostroumova TM, Klepikova MV, Aljautdinova IA, Goloborodova IV. Drug-induced diseases: approaches to diagnosis, correction, and prevention. Pharmacovigilance. Farmateka 2020;27(6):113-26 (In Russian).
9. Camus P. The drug-induced respiratory disease website. Available from: www.pneumotox.com Accessed 2022 Feb 24.
10. Kupczyk M, Kupryś I, Górski P, Kuna P. Aspirin intolerance and allergy to house dust mites: important factors associated with development of severe asthma. Annals of Allergy, Asthma & Immunology 2004 Apr;92(4):453-8.
11. Mascia K, Haselkorn T, Deniz YM, Miller DP, Bleecker ER, Borish L; TENOR Study Group. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. The Journal of Allergy and Clinical Immunology 2005 Nov;116(5):970-5.
12. Plaza V, Serrano J, Picado C, Sanchis J; High Risk Asthma Research Group. Frequency and clinical characteristics of rapid-onset fatal and near-fatal asthma. The European Respiratory Journal 2002 May;19(5):846-52.
13. Ta V, White AA. Survey-defined patient experiences with aspirin exacerbated respiratory disease. The Journal of Allergy and Clinical Immunology. In Practice 2015 Sep-Oct;3(5):711-8.
14. Bennett M, Chang CL, Tatley M, Savage R, Hancox RJ. The safety of cardioselective β1-blockers in asthma: literature review and search of global pharmacovigilance safety reports. ERJ. Open Research 2021 Mar;7(1):00801-2020.
15. Fraunfelder FT, Barker AF. Respiratory effects of timolol. The New England Journal of Medicine 1984 Nov;311(22):1441.
16. Taniguchi M, Kino H, Mori M, Nakahama M. [A case of fatal asthma induced by timolol eye-drop]. Nihon Kyobu Shikkan Gakkai Zasshi 1990 Jan;28(1):156-9.
17. Vorzheva II, Chernyak BA. Aspirin-exacerbated respiratory disease: mechanisms of development, diagnostics and treatment. Farmateka 2018;8(361):24-33 (In Russian).
18. Steinke JW, Wilson JM. Aspirin-exacerbated respiratory disease: pathophysiological insights and clinical advances. Journal of Asthma and Allergy 2016 Mar;9:37-43.
19. Tuttle KL, Schneider TR, Henrickson SE, Morris D, Abonia JP, Spergel JM, Laidlaw TM. Aspirin-exacerbated respiratory disease: not always “adult-onset”. The Journal of Allergy and Clinical Immunology. In Practice 2016;4(4):756-8.
20. Guillén D, Bobolea L, Calderon O, Fiandor A, Cabañas R, Heredia R, Quirce S. Aspirin desensitization achieved after omalizumab treatment in a patient with aspirin exacerbated urticaria and respiratory disease. Journal of Investigational Allergology and Clinical Immunology 2015;25(2):133-5.
21. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clinical Pharmacology & Therapeutics 1981 Aug;30(2):239-45.
22. Ministry of Health of the Russian Federation; Russian Respiratory Society; Russian Association of Allergologists and Clinical Immunologists. Clinical recommendations. Bronchial asthma. Year of approval: 2018. Moscow, 90 p. Available from: https://spulmo.ru/download/asthma2018.pdf Accessed 2022 Feb 24. (In Russian).
23. Sommer DD, Rotenberg BW, Sowerby LJ, Lee JM, Janjua A, Witterick IJ, Monteiro E, Gupta MK, Au M, Nayan S. A novel treatment adjunct for aspirin exacerbated respiratory disease: the low-salicylate diet: a multicenter randomized control crossover trial. International Forum of Allergy & Rhinology 2016 Apr;6(4):385-91.

  

[ Содержание выпуска N 4 | Выпуски журнала | Список журналов ]